Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
Crossref DOI link: https://doi.org/10.1007/s40258-016-0243-4
Published Online: 2016-04-18
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sabater, Eliazar
López-Guillermo, Armando
Rueda, Antonio
Salar, Antonio
Oyagüez, Itziar
Collar, Juan Manuel
Text and Data Mining valid from 2016-04-18